Anti-CDKN1A/p21CIP1 Rabbit Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - P38936

Core Product Specifications and Parameters

Biological Background: CDKN1A/p21CIP1 Function and Localization

• CDKN1A/p21CIP1 is a cyclin-dependent kinase inhibitor that plays a critical role in controlling cell cycle progression and DNA damage-induced G2 arrest (PubMed:9106657). Related references: PMID:9106657
• The protein acts as a key mediator of p53/TP53-dependent inhibition of cell proliferation in response to DNA damage, and also participates in p53-independent G2 arrest pathways in certain cell types.
• p21 binds to and inhibits the activity of cyclin-dependent kinases, preventing phosphorylation of critical substrates like RB1 to block cell cycle progression; it also facilitates nuclear localization and assembly of the cyclin D-CDK4 complex, with its effect on kinase activity being stoichiometry-dependent.
• It inhibits DNA synthesis by binding to PCNA (proliferating cell nuclear antigen) and competing with POLD3 for PCNA binding, thereby blocking DNA polymerase delta processivity (PubMed:11595739). Related references: PMID:11595739
• CDKN1A localizes to both the cytoplasm and nucleus, allowing it to regulate cell cycle machinery and other processes in multiple subcellular compartments.
• Expressed ubiquitously across adult tissues, with notably lower levels in the brain.
• The protein features a zinc-finger domain and is subject to post-translational modifications including phosphorylation and acetylation, which modulate its stability and interactions.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide spanning amino acids 1-164 of human p21; this region includes the N-terminal domain involved in CDK and cyclin binding, potentially yielding antibodies that recognize the native and denatured protein.
• For Western blot (WB) analysis, a band at approximately 18 kDa corresponding to p21 is anticipated; however, due to post-translational modifications, slight shifts may be observed.
• When performing immunohistochemistry (IHC-P) or immunofluorescence (IF/ICC), optimization of sample preparation and antigen retrieval may be necessary to achieve robust staining.
• The antibody’s cross-reactivity with mouse and rat p21 has been noted, but it is advisable to verify specificity in the target tissue or cell line of interest.
• For ELISA applications, preliminary checkerboard titrations are recommended to determine the optimal coating and detection antibody concentration.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with comprehensive access to IVD raw materials and technical support, from concept to clinic. This anti-CDKN1A/p21CIP1 polyclonal antibody supports cell cycle and oncology research. Beyond individual antibodies, we offer validated antibody pairs, optimized monoclonals, bulk ancillary reagents, and custom sourcing for rare targets—ensuring a seamless procurement experience for your assay development needs.